Search results for: Multi-Indication Medicines
Filter search results
The Inflation Reduction Act: Price negotiation underway for the first 10 drugs
29 November 2023
…investigated and identified after initial FDA approval. This is particularly true of oncology drugs, but multi-indication medicines are common across therapy areas. If manufacturers expect a price cut to be…
Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward
1 December 2018
…current approaches to MIP in Europe, the perceived challenges, and how they could be tackled in the future. Multi-indication pricing (MIP) is based on the idea of recognising the value…
Recent Statistics on Orphan Approvals in Scotland and England
23 August 2011
…the 74 orphan indications approved by the European Medicines Agency (EMA) up to May 2011. The SMC has issued 55 decisions for the 74 orphan indications. Because of resubmissions and…
OHE at AES 2016: Early Access Schemes, Equity Adjusted QALYs, Multi-indication Pricing and Formulary Development
2 August 2016
…their activity. Multi-Indication Pricing: Pros, Cons and Applicability to the UK by Jorge Mestre-Ferrandiz Multi-indication pricing (MIP) involves setting a different price for each indication approved for a medicine. The…
OHE at ISPOR May 2016: Meet the Team
19 May 2016
…Multi-Indication Pricing: Pros, Cons and its Applicability to the UK OHE Authors: Jorge Mestre-Ferrandiz and Adrian Towse Time and date: Monday 23rd May, 3:45pm. Summary: Multi-indication pricing (MIP) involves setting…
Plan For A New EU Pharmaceutical Legislation: What Will It Mean For Pharmaceutical Innovation?
12 April 2024
…Intellectual Property. [online] Available at: https://www.efpia.eu/about-medicines/development-of-medicines/intellectual-property/ [Accessed 11 Apr. 2024]. European Medicines Agency and Sonia Ribeiro, 2018. Data exclusivity, market protection, orphan and paediatric rewards. [online] Available at: https://www.ema.europa.eu/en/documents/presentation/presentation-data-exclusivity-market-protection-orphan-and-paediatric-rewards-s-ribeiro_en.pdf [Accessed 5 Apr. 2024]. European…
Ethical and Economic Issues in the Appraisal of Medicines for Ultra-rare (or Ultra-orphan) Conditions
13 January 2020
…for medicines for more common conditions, may not be appropriate for medicines for ultra-rare conditions. Previous OHE research on availability and access to medicines for rare conditions (also known as…
Assessing the Life-cycle Value of Second-generation Antipsychotics in Sweden and the UK
17 July 2019
…A. & Zamora, B., 2019. Indication-Based Pricing (IBP) Discussion Paper. OHE Briefing, London: Office of Health Economics. Available at: https://www.ohe.org/publications/indication-based-pricing-ibp-discussion-paper-should-drug-prices-differ-indication Lakdawalla, D., MacEwan, J.P., Dubois, R., Westrich, K., Berdud,…
Reasons for Discontinuation of R&D Projects: Lead and Follow-on Indications
12 March 2013
…lead indications were consistent with previous findings; to our knowledge, this is the first analysis of discontinuations of follow-on indications. Companies also were asked their opinions on what factors may…